Stay updated with breaking news from Iological Marker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patient selection and discussions surrounding side effects and expectations are key when considering prescribing lecanemab and potentially other therapies targeting brain amyloid.
Using early-response biomarkers in patients treated with lutetium-177 PSMA-617 can help personalize dosing intervals and potentially improve outcomes.
A study has uncovered an association between elevated levels of two Alzheimer’s disease biomarkers and reduced levels of neuroprotective bacteria in the digestive system.
An experimental tau aggregation inhibitor significantly reduced tau, an established biomarker of neurodegeneration, which correlated with changes in cognitive test scores.
An easy-to-administer method of blood collection could facilitate accurate diagnoses and regular monitoring of patients with suspected cognitive impairment.